Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for functional adrenal tumors, which is in Phase II study. It also develops anti-GlycoTarget antibodies to treat solid tumors. In addition, the company's PentixaFor is being developed as a diagnostic tool for primary hypertension, a cause of hypertension, which is in Phase III trial. Further, its pipeline products for oncology indications include PT-00X, GT-00X, GT-001, GT-002, GT-005, and GT-008. Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.